Search
Nitroxoline
go.drugbank.com/drugs/DB01422ExperimentalNitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. … It is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.
Maltotetraose
go.drugbank.com/drugs/DB02237ExperimentalCategories: Compounds used in a research, industrial, or household settingNeisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15680ApprovedInvestigationalZEN-012
go.drugbank.com/drugs/DB06042ExperimentalZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. … It is developed for the treatment of solid tumors.
Phosmet
go.drugbank.com/drugs/DB11448ExperimentalVet approvedPhosmet is a phthalimide-derived organophosphate. It is a non-specific insecticide. It is mainly used on apple trees to control codling moths. … It is also used on other fruit crops, ornamentals, and vines to control aphids, suckers, mites, and fruit flies.
Categories: Compounds used in a research, industrial, or household settingCMLVAX100
go.drugbank.com/drugs/DB05164ExperimentalCMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. … It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Deserpidine
go.drugbank.com/drugs/DB01089ApprovedWithdrawnDeserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X.
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment